498 related articles for article (PubMed ID: 38339274)
1. Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.
Maekawa S; Takata R; Obara W
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339274
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
3. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
4. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
Isaacsson Velho P; Carducci MA
Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
[TBL] [Abstract][Full Text] [Related]
5. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
6. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC
Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor-Related Non-coding RNAs in Prostate Cancer.
Yang Y; Liu KY; Liu Q; Cao Q
Front Cell Dev Biol; 2021; 9():660853. PubMed ID: 33869227
[TBL] [Abstract][Full Text] [Related]
8. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
9. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
12. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways.
Tortorella E; Giantulli S; Sciarra A; Silvestri I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768370
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth.
Luo J; Wang D; Wan X; Xu Y; Lu Y; Kong Z; Li D; Gu W; Wang C; Li Y; Ji C; Gu S; Xu Y
Onco Targets Ther; 2020; 13():9257-9267. PubMed ID: 32982312
[TBL] [Abstract][Full Text] [Related]
15. Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.
Zhu W; Wan F; Xu W; Liu Z; Wang J; Zhang H; Huang S; Ye D
Clin Transl Med; 2022 Sep; 12(9):e1028. PubMed ID: 36169095
[TBL] [Abstract][Full Text] [Related]
16. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications.
Pisano C; Tucci M; Di Stefano RF; Turco F; Scagliotti GV; Di Maio M; Buttigliero C
Crit Rev Oncol Hematol; 2021 Jan; 157():103185. PubMed ID: 33341506
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1.
Makino Y; Kamiyama Y; Brown JB; Tanaka T; Murakami R; Teramoto Y; Goto T; Akamatsu S; Terada N; Inoue T; Kodama T; Ogawa O; Kobayashi T
Commun Biol; 2022 Apr; 5(1):299. PubMed ID: 35365763
[TBL] [Abstract][Full Text] [Related]
18. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells.
Luo H; Liu Y; Li Y; Zhang C; Yu B; Shao C
FASEB J; 2022 Sep; 36(9):e22495. PubMed ID: 35947121
[TBL] [Abstract][Full Text] [Related]
20. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
Sun R; Wei T; Ding D; Zhang J; Chen S; He HH; Wang L; Huang H
Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2205509119. PubMed ID: 36129942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]